Table 3.
Subgroup analyses of the discriminatory power of platelets (PLT), total bilirubin (T‐Bil), and prothrombin time – international normalized ratio (PT‐INR) on postoperative day (POD)‐7 and ‐14 for recipient 6‐month survival after living‐donor liver transplantation
| AUROC (95% CI) | ||||||||
|---|---|---|---|---|---|---|---|---|
| PLT | T‐Bil | INR | Three factors combined | |||||
| POD‐7 | POD‐14 | POD‐7 | POD‐14 | POD‐7 | POD‐14 | POD‐7 | POD‐14 | |
| Donor age | ||||||||
| ≥50 years (n = 165) | 0.72 (0.60–0.81) | 0.81 (0.70–0.89) | 0.63 (0.50–0.74) | 0.76 (0.65–0.84) | 0.67 (0.52–0.79) | 0.74 (0.61–0.84) | 0.73 (0.61–0.83) | 0.82 (0.73–0.89) |
| <50 years (n = 235) | 0.71 (0.60–0.80) | 0.87 (0.77–0.93) | 0.71 (0.60–0.79) | 0.87 (0.79–0.92) | 0.74 (0.62–0.83) | 0.82 (0.72–0.89) | 0.78 (0.67–0.86) | 0.89 (0.82–0.94) |
| Graft type | ||||||||
| Right lobe (n = 246) | 0.76 (0.64–0.86) | 0.88 (0.77–0.94) | 0.67 (0.56–0.77) | 0.84 (0.75–0.90) | 0.71 (0.57–0.81) | 0.83 (0.73–0.90) | 0.77 (0.65–0.86) | 0.90 (0.82–0.95) |
| Left lobe (n = 153) | 0.64 (0.53–0.73) | 0.79 (0.68–0.86) | 0.67 (0.54–0.77) | 0.79 (0.68–0.87) | 0.68 (0.55–0.79) | 0.71 (0.58–0.81) | 0.73 (0.61–0.82) | 0.80 (0.70–0.88) |
| ABO compatibility | ||||||||
| Incompatible (n = 99) | 0.63 (0.48–0.75) | 0.73 (0.59–0.84) | 0.58 (0.44–0.71) | 0.78 (0.66–0.87) | 0.65 (0.47–0.79) | 0.70 (0.55–0.82) | 0.67 (0.51–0.79) | 0.80 (0.68–0.88) |
| Not (n = 301) | 0.76 (0.67–0.83) | 0.88 (0.80–0.93) | 0.73 (0.63–0.80) | 0.83 (0.75–0.89) | 0.75 (0.65–0.83) | 0.83 (0.76–0.89) | 0.81 (0.72–0.88) | 0.89 (0.82–0.94) |
| MELD score | ||||||||
| ≥20 (n = 155) | 0.69 (0.57–0.79) | 0.79 (0.66–0.87) | 0.60 (0.46–0.72) | 0.76 (0.64–0.85) | 0.61 (0.46–0.74) | 0.72 (0.59–0.83) | 0.68 (0.55–0.79) | 0.80 (0.68–0.87) |
| <20 (n = 245) | 0.73 (0.62–0.82) | 0.88 (0.80–0.93) | 0.73 (0.63–0.81) | 0.86 (0.79–0.92) | 0.78 (0.68–0.86) | 0.82 (0.73–0.88) | 0.81 (0.70–0.88) | 0.91 (0.84–0.95) |
| GRWR | ||||||||
| ≥0.8% (n = 282) | 0.72 (0.63–0.80) | 0.84 (0.76–0.90) | 0.68 (0.59–0.76) | 0.83 (0.76–0.88) | 0.72 (0.62–0.81) | 0.81 (0.73–0.87) | 0.78 (0.69–0.85) | 0.88 (0.81–0.92) |
| <0.8% (n = 118) | 0.71 (0.55–0.83) | 0.86 (0.72–0.94) | 0.68 (0.51–0.81) | 0.86 (0.76–0.92) | 0.68 (0.49–0.82) | 0.71 (0.52–0.85) | 0.73 (0.54–0.86) | 0.87 (0.78–0.93) |
| Risk factors combined | ||||||||
| Donor age <50 years/Right lobe (n = 129) | 0.78 (0.58–0.90) | 0.89 (0.74–0.96) | 0.72 (0.56–0.84) | 0.87 (0.75–0.94) | 0.68 (0.47–0.83) | 0.84 (0.65–0.93) | 0.76 (0.58–0.88) | 0.93 (0.81–0.98) |
| Donor age <50 years/Not incompatible (n = 178) | 0.76 (0.64–0.86) | 0.93 (0.82–0.97) | 0.78 (0.64–0.88) | 0.90 (0.81–0.96) | 0.76 (0.61–0.87) | 0.85 (0.73–0.92) | 0.84 (0.69–0.92) | 0.93 (0.82–0.98) |
| Donor age <50 years/MELD <20 (n = 141) | 0.66 (0.51–0.78) | 0.86 (0.74–0.93) | 0.73 (0.60–0.84) | 0.88 (0.77–0.94) | 0.76 (0.60–0.87) | 0.82 (0.69–0.90) | 0.77 (0.62–0.87) | 0.90 (0.79–0.95) |
| Right lobe/Not incompatible (n = 194) | 0.83 (0.70–0.91) | 0.91 (0.76–0.97) | 0.77 (0.64–0.86) | 0.88 (0.78–0.94) | 0.76 (0.60–0.86) | 0.86 (0.77–0.92) | 0.86 (0.74–0.93) | 0.93 (0.81–0.97) |
| Right lobe/MELD <20 (n = 160) | 0.76 (0.60–0.87) | 0.92 (0.80–0.97) | 0.72 (0.58–0.83) | 0.87 (0.77–0.93) | 0.78 (0.62–0.89) | 0.87 (0.73–0.94) | 0.81 (0.65–0.90) | 0.94 (0.85–0.98) |
| Not incompatible/MELD <20 (n = 183) | 0.78 (0.64–0.87) | 0.94 (0.85–0.98) | 0.78 (0.64–0.87) | 0.88 (0.79–0.94) | 0.81 (0.67–0.90) | 0.85 (0.74–0.91) | 0.85 (0.71–0.93) | 0.94 (0.84–0.98) |
Area under the receiver operating characteristic curve (AUROCs) were calculated by the combination of the three factors on POD‐7 and ‐14, and the results are highlighted in bold.
CI, confidence interval; GRWR, graft‐versus‐recipient weight ratio; MELD, Model for End‐stage Liver Disease.